Icon

Kisqali Femara Co-Pack - (200 mg and 2.5 mg, Tablet)

Ribociclib Succinate and Letrozole (Copackaged) Novartis
200 mg and 2.5 mg, Tablet
Less Than $1000 mn
Less Than 5
Less Than 5
None
Less Than 5
None None
KISQALI FEMARA CO-PACK, a co-packaged product containing ribociclib, a kinase inhibitor, and letrozole, an aromatase inhibitor, is indicated as initial endocrine-based therapy for the treatment of postmenopausal women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer.
Yes
******** **** ********* **** (*** ** * ***) ** **** **, **** ** ******* ** '***, '***, '***, '***, '***, '***, '*** *** '***. ******** **** *** *** (*** ** * *** ******) ** **** **, **** ** ******* ** '***, '***, '***, '*** *** '***.
Kisqali Femara Co-Pack Patent 1 Patent 2 Patent 3 Patent 4 Patent 5 Patent 6 Patent 7 Patent 8
********* **** ******* ******* ******* ******* ******* ******* ******* *******
*** **** **** ** **** **, **** **** ** **** **, **** **** ** **** **, **** **** ** **** **, **** *** ********* **** ** **** **, **** *** ********* *** *********
Company FTF Status / 180 days exclusivity 30-Months stay Current Litigation Status Current Approval Status Likelihood of launch
********* **** *** \ ********* *** **, **** ******* **** ******* *** **** *** *** ****
*** **** *** \ *** *** **, **** ******* ********* ******** *** ****** *** ****
  1. *** **, **** : * ****-** ** ***** *** ***** *** **** *** *********.
  2. *** **, **** : ******** **** ********* **** ******* ** '***, '***, '***, '***, '***, '***, '*** *** '***.
  3. *** *, **** : ******** **** *** *** ** ******* ** '***, '***, '***, '*** *** '***.
  4. *** **, **** : ******** *** ********* ******* ********** ** ******* *****.

Download ParaIV Report


Download ParaIV Detailed Report


To get detailed report Contact Us

ParaIV Advanced Search






Please contact contact@researchdelta.com to get more details.